Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

Published:2015-01-15 Issue:3 Volume:125 Page:449-456
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Sonneveld Pieter¹,Asselbergs Emilie¹,Zweegman Sonja²,van der Holt Bronno³,Kersten Marie Jose⁴,Vellenga Edo⁵,van Marwijk-Kooy Marinus⁶,Broyl Annemiek¹,de Weerdt Okke⁷,Lonergan Sarah⁸,Palumbo Antonio⁹,Lokhorst Henk¹⁰

Affiliation:

1. Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;

2. Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;

3. HOVON Data Center, Erasmus MC Cancer Institute, Clinical Trial Center, Rotterdam, The Netherlands;

4. Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands;

5. Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands;

6. Department of Hematology, Isala Clinics, Zwolle, The Netherlands;

7. Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands;

8. Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands;

9. Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy; and

10. Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands

Abstract

Key Points KTd is an effective induction and consolidation regimen for transplant-eligible MM patients. The KTd regimen is safe and well tolerated with a notable lack of peripheral neuropathy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/3/449/1344262/449.pdf

Reference36 articles.

1. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.;Lahuerta;J Clin Oncol,2008

2. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.;Harousseau;J Clin Oncol,2009

3. CR represents an early index of potential long survival in multiple myeloma.;Wang;Bone Marrow Transplant,2010

4. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.;van de Velde;Haematologica,2007

5. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.;Moreau;Blood,2011

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma;Clinical and Translational Science;2024-05

2. Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial;British Journal of Haematology;2023-06-18

3. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy;Current Problems in Cardiology;2023-03

5. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS);European Heart Journal;2022-08-26